An international comparative analysis and roadmap to sustainable biosimilar markets
Background: Although biosimilar uptake has increased (at a variable pace) in many countries, there have been recent concerns about the long-term sustainability...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA’s policy team provides analysis and insights into global, regional and national policy issues affecting patients, the healthcare system, and the life sciences industry. CRA has a reputation for independence and rigor, benefiting from long standing relationships with most leading life sciences organizations as well as national governments and the European Commission and industry associations. Our specialist team has provided unique policy oversight for the past 20 years delivering high quality, robust analysis but in a compelling fashion that is accessible to the target audience, whomever it may be.
Background: Although biosimilar uptake has increased (at a variable pace) in many countries, there have been recent concerns about the long-term sustainability...
Early access to curative therapies is vital to support the clinical benefits they can provide to both patients and healthcare systems. Early access programs...
Rajini Jayasuriya is a panelist on “Life Sciences Around the Globe: Exploring Key International Developments Impacting the Global Life Sciences Stage” and will...
Hannah Armstrong presents during the session titled “Building a healthier world: Tackling AMR.” For more information on this event, click here.